Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition.
about
The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in TherapyCardioprotective interventions for cancer patients receiving anthracyclinesCardioprotective interventions for cancer patients receiving anthracyclinesResearch progress of cardioprotective agents for prevention of anthracycline cardiotoxicity.Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprololAutonomic dysfunction in early breast cancer: Incidence, clinical importance, and underlying mechanismsCardiac toxicity in cancer survivorsUnderstanding cardiovascular injury after treatment for cancer: an overview of current uses and future directions of cardiovascular magnetic resonanceCardiac effects of anticancer therapy in the elderlyCardiovascular Health of Patients With Cancer and Cancer Survivors: A Roadmap to the Next LevelEvaluation and management of patients with heart disease and cancer: cardio-oncologySerum biomarkers for the detection of cardiac toxicity after chemotherapy and radiation therapy in breast cancer patientsUse of biomarkers for the assessment of chemotherapy-induced cardiac toxicity.Cardio-Oncology: A Focused Review of Anthracycline-, Human Epidermal Growth Factor Receptor 2 Inhibitor-, and Radiation-Induced Cardiotoxicity and ManagementPotential Therapeutic Strategies for Hypertension-Exacerbated Cardiotoxicity of Anticancer DrugsTwenty years of anti-HER2 therapy-associated cardiotoxicityCardiac risk in the treatment of breast cancer: assessment and management.Challenges in acute heart failure clinical management: optimizing care despite incomplete evidence and imperfect drugsRecent Advances on Pathophysiology, Diagnostic and Therapeutic Insights in Cardiac Dysfunction Induced by Antineoplastic DrugsMedical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer.Chemotherapy-Induced Cardiotoxicity: Pathophysiology and PreventionCancer therapy-induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies.Management of chemotherapy induced cardiomyopathy.Noninvasive diagnosis of chemotherapy related cardiotoxicityCardio-oncology: a new medical issue.Cardiovascular, diabetes, and cancer strips: evidences, mechanisms, and classifications.Clozapine in a patient with treatment-resistant schizophrenia and hypertrophic cardiomyopathy: a case report.Cardio-oncology in targeting the HER receptor family: the puzzle of different cardiotoxicities of HER2 inhibitors.Diagnostic Strategies for Early Recognition of Cancer Therapeutics-Related Cardiac Dysfunction.Late effects of blood and marrow transplantation.The art of healing broken hearts in breast cancer patients: Trastuzumab and heart failure.Creating a Biomarker Panel for Early Detection of Chemotherapy Related Cardiac Dysfunction in Breast Cancer PatientsAssessment of cardiotoxicity with cardiac biomarkers in cancer patients.Cardiovascular Late Effects and Exercise Treatment in Breast Cancer: Current Evidence and Future DirectionsPooled analysis of cardiac safety in patients with cancer treated with pertuzumab.Cardiovascular disease in adult survivors of childhood cancer.Network-based analysis reveals distinct association patterns in a semantic MEDLINE-based drug-disease-gene network.Anthracycline-associated cardiotoxicity in survivors of childhood cancer.Cardiovascular toxicities from systemic breast cancer therapy.Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment
P2860
Q21284978-9422FD3C-9178-430F-B9A4-5E2ACA3ED4E4Q24236338-31403088-FD75-428F-B623-110A819A1A08Q24243021-FC34EC31-443E-471D-B924-FE33333020C6Q26742059-040A81DD-A3BA-42CA-8057-78B7E1429BAEQ26768272-960C518E-E05C-420F-B1BF-8079DF90580DQ26795624-AE3CD5F6-B0E4-4995-BE40-64C9FBE87F2DQ26851957-3D5BDA06-E17D-4DA6-B6CD-6C436C29E800Q26859193-129D38B7-4F69-4C95-8A3B-342C34F2A9B6Q26863244-9E5DE4E9-C678-493C-8344-B16AC2B6A0B7Q26864094-54CFE00F-2841-4B3F-AF7D-60AD1354F43FQ26998273-17DFAC64-107A-457E-BA90-9A6E5CE322CDQ27007849-517D5AA1-9639-4537-8A46-28DC4A7EAA99Q27027354-BCA27E75-67F9-462A-B566-449E0FD8A55EQ28068290-7D633A5A-DA96-4C02-9C84-2C5A436D10A2Q28070311-99B944CD-454D-40A4-A6ED-04A917B705D7Q28079391-88F6A6D2-CA70-46AC-9C9D-92AB55FBBD88Q28081385-FFF3B08E-7606-46D7-BBCC-1AD41C14CCCCQ28085736-10DAE737-A463-440E-A510-AE76C846C855Q28087776-B5704D0E-A87C-4D83-A0D3-21084DB21D32Q30248340-C422DE14-7F06-4740-BAE9-A52C9AD63322Q30399577-EDCE89E0-0328-4D5A-8A30-6B94693FC08BQ30426853-74ED3674-AAC4-4276-82E5-941E2378A6A4Q30461441-AE018B02-387C-43DE-9B3F-B0491752BF62Q30461444-EBF9D116-C7A6-4C5A-B3EE-3AE4E7F7FFB0Q30471284-9C51367C-0552-4F36-8E6E-E9F631A138D3Q30487342-2881F26B-6EA4-4B0B-B385-6F37C6CE5101Q30490810-2CD93E34-0671-440A-879E-74346542572DQ33352155-1D362270-BAA9-4C3C-9955-A1DA33E4FC04Q33565936-7B0AFEC2-1513-43B7-A28A-46914B8DE154Q33574136-D3C67A0F-4FAD-481C-B2EF-7E1F500602D3Q33595716-38D6375A-E119-482C-B11F-BC1BFE7E5EA8Q33816471-A1CEE5EA-946C-4364-8746-E64FA0FAEC35Q33896047-10FA597D-3759-478E-A19D-3D1008F703BBQ33907581-5B4F461D-A15A-454C-8A33-D1312A046112Q33930241-B13B4328-81A5-4B5E-8BBD-8E03F1D71985Q34042984-51B66A24-BB10-4C93-B279-3B08B7424730Q34064935-FED77D84-C98B-4957-A744-A15E75F6F3A6Q34626238-3AC46AD6-4AEF-4020-AEF0-6F94687DC70DQ34630349-B9F88AA6-1EE8-4518-A568-58E7955863F3Q34639876-390FC009-5C40-472C-9860-F3B753B456D0
P2860
Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition.
description
2006 nî lūn-bûn
@nan
2006 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Prevention of high-dose chemot ...... -converting enzyme inhibition.
@ast
Prevention of high-dose chemot ...... -converting enzyme inhibition.
@en
Prevention of high-dose chemot ...... -converting enzyme inhibition.
@nl
type
label
Prevention of high-dose chemot ...... -converting enzyme inhibition.
@ast
Prevention of high-dose chemot ...... -converting enzyme inhibition.
@en
Prevention of high-dose chemot ...... -converting enzyme inhibition.
@nl
prefLabel
Prevention of high-dose chemot ...... -converting enzyme inhibition.
@ast
Prevention of high-dose chemot ...... -converting enzyme inhibition.
@en
Prevention of high-dose chemot ...... -converting enzyme inhibition.
@nl
P2093
P1433
P1476
Prevention of high-dose chemot ...... -converting enzyme inhibition.
@en
P2093
Alessandro Colombo
Carlo M Cipolla
Cesare Fiorentini
Daniela Cardinale
Fabrizio Veglia
Giuseppina Lamantia
Maria T Sandri
Maurizio Civelli
Nicola Colombo
P304
P356
10.1161/CIRCULATIONAHA.106.635144
P407
P577
2006-11-13T00:00:00Z